Mochi Health Weight Loss / GLP-1 Review

What we couldn't verify

• joinmochi.com/pricing and /eligibility returned 404; on-site pricing/eligibility corroborated via aggregators. Trustpilot now verified 4.4/16,273 (rendered fetch 2026-07-24).
• Specific BMI/age eligibility thresholds are not published on Mochi's site (assessed only during the live consult).
• Current active compounding-pharmacy partners (Seven Cells, Drug Crafters) and their 503A/503B status post-Aequita are reported by third parties, not confirmed on a primary Mochi page.
• Whether Mochi specifically received a Sept-2025 FDA marketing warning letter (vs the industry-wide wave) was not confirmed from a primary FDA source.
• Withdrawn — Some customers reported serious illness after injections. "Some customers reported serious illness after injections" is WITHDRAWN. It is an affirmative ADVERSE claim, and the source is a news digest summarising KING 5's reporting (fetched 2026-08-10) — not a primary record. Adverse claims require a primary source; no FDA adverse-event record, regulator finding or registry entry establishes patient illness attributable to Mochi.
• Withdrawn — Mochi's LegitScript certification. Mochi's LegitScript certification is WITHDRAWN as a stated fact. The source returned HTTP 403 (recorded as retrieval-failed, not disproved), and the claim appears nowhere on joinmochi.com/weight-loss (fetched 2026-08-10). Mirrors the treatment applied to Sprout Health's unverifiable LegitScript claim. SPLIT 2026-08-25: this entry previously bundled the "all 50 states + DC" availability claim with the LegitScript one and withdrew both. The availability half was REINSTATED on 2026-08-11 — "Correction in Mochi's favour: its availability in all 50 states is stated plainly on its own About page… it is restored" — but this entry was never updated, so gaps[] and the review history contradicted each other on a published page. Only the LegitScript half remains withdrawn. Recorded separately and not decided here: the read that reinstated availability was a raw fetch of joinmochi.com, which is now refused on terms — an open question, not a reason to re-withdraw.
• Withdrawn — Mochi's HIPAA-compliance and LegitScript claims. Mochi's HIPAA-compliance and LegitScript claims are WITHDRAWN as sourced facts: the third-party page asserting them returned HTTP 403, and joinmochi.com/weight-loss states neither (fetched 2026-08-10). The verified San Francisco address is not in dispute; the compliance claims are simply unverified.
• data-privacy-security: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. The withdrawn claim was a third party's assertion that Mochi is HIPAA compliant. We found no privacy or HIPAA page on joinmochi.com to check it against (/privacy and /legal both 404). Absent a page to read, we have not established non-disclosure — only that we could not find it.
• glp1-titration-autonomy: re-encoded as a RETRIEVAL GAP (excluded, re-normalized out of the score) rather than brand opacity. The withdrawn claim was "some customers reported serious illness after injections" — an ADVERSE claim WE published and could not source to a primary record. Leaving a subscore penalty on Mochi for an accusation we retracted is the single most objectionable form of this defect.
• Withdrawn — Claims that Aequita Pharmacy "illegally imported cheap GLP-1 bulk ingredients" and "substituted medical-grade supplies with Alibaba vials". Claims that Aequita Pharmacy "illegally imported cheap GLP-1 bulk ingredients" and "substituted medical-grade supplies with Alibaba vials" are WITHDRAWN. They rested solely on a KING 5 investigation which we could not retrieve (HTTP 403 to a direct fetch, timeout to our fetcher), and the Washington DOH notice — which we CAN retrieve — cites untrained staff, inadequate supervision and sterile-procedure failures, but says nothing about importation or vial substitution. Withdrawn for want of a retrievable source, not disproved. (2026-08-11)
• Withdrawn — unlicensed temporary workers picked up at home improvement store parking lots. Claims that Aequita used "unlicensed temporary workers picked up at home improvement store parking lots" and that "at least three GLP-1 prescriptions expired nearly nine months before mailing to patients" are WITHDRAWN — KING 5-only, and unretrievable by us (403 / timeout). The Washington DOH notice covers untrained and unsupervised staff but neither of those specifics. Withdrawn for want of a retrievable source, not disproved. (2026-08-11)
• Withdrawn — at least three GLP-1 prescriptions expired nearly nine months before mailing to patients. Claims that Aequita used "unlicensed temporary workers picked up at home improvement store parking lots" and that "at least three GLP-1 prescriptions expired nearly nine months before mailing to patients" are WITHDRAWN — KING 5-only, and unretrievable by us (403 / timeout). The Washington DOH notice covers untrained and unsupervised staff but neither of those specifics. Withdrawn for want of a retrievable source, not disproved. (2026-08-11)
• Withdrawn — figure "~20,000 prescriptions per week at peak". The figure "~20,000 prescriptions per week at peak" is WITHDRAWN. NBC Bay Area attributed it to "inspectors said in their findings" — a paraphrase of an upstream regulator record — and the Washington DOH notice we CAN retrieve contains no volume figure of any kind (checked 2026-08-11). We do not keep a number that reaches us by paraphrase. Separately, the "safety scandal" characterisation is withdrawn: NBC sourced patient-harm claims to whistleblower accounts it obtained, and no primary record establishes patient harm. (2026-08-11)